Show simple item record

dc.contributor.authorGómez-Acebo, Inés
dc.contributor.authorDierssen-Sotos, Trinidad
dc.contributor.authorMirones, Mónica
dc.contributor.authorPerez-Gomez, Beatriz 
dc.contributor.authorGuevara, Marcela
dc.contributor.authorAmiano, Pilar
dc.contributor.authorSala, María
dc.contributor.authorMolina, Antonio J
dc.contributor.authorAlonso-Molero, Jéssica
dc.contributor.authorMoreno, Victor
dc.contributor.authorSuarez-Calleja, Claudia
dc.contributor.authorMolina-Barceló, Ana
dc.contributor.authorAlguacil, Juan
dc.contributor.authorMarcos-Gragera, Rafael
dc.contributor.authorFernández-Ortiz, María
dc.contributor.authorSanz-Guadarrama, Oscar
dc.contributor.authorCastaño-Vinyals, Gemma
dc.contributor.authorGil-Majuelo, Leire
dc.contributor.authorMoreno-Iribas, Conchi
dc.contributor.authorAragones, Nuria 
dc.contributor.authorKogevinas, Manolis
dc.contributor.authorPollan-Santamaria, Marina 
dc.contributor.authorLlorca, Javier
dc.identifier.citationSci Rep. 2021 Mar 8;11(1):5375.es_ES
dc.description.abstractThe St Gallen Conference endorsed in 2013 a series of recommendations on early breast cancer treatment. The main purpose of this article is to ascertain the clinical factors associated with St Gallen-2013 recommendations accomplishment. A cohort of 1152 breast cancer cases diagnosed with pathological stage < 3 in Spain between 2008 and 2013 was begun and then followed-up until 2017/2018. Data on patient and tumour characteristics were obtained from medical records, as well as their first line treatment. First line treatments were classified in three categories, according on whether they included the main St Gallen-2013 recommendations, more than those recommended or less than those recommended. Multinomial logistic regression models were carried out to identify factors associated with this classification and Weibull regression models were used to find out the relationship between this classification and survival. About half of the patients were treated according to St Gallen recommendations; 21% were treated over what was recommended and 33% received less treatment than recommended. Factors associated with treatment over the recommendations were stage II (relative risk ratio [RRR] = 4.2, 2.9-5.9), cancer positive to either progesterone (RRR = 8.1, 4.4-14.9) or oestrogen receptors (RRR = 5.7, 3.0-11.0). Instead, factors associated with lower probability of treatment over the recommendations were age (RRR = 0.7 each 10 years, 0.6-0.8), poor differentiation (RRR = 0.09, 0.04-0.19), HER2 positive (RRR = 0.46, 0.26-0.81) and triple negative cancer (RRR = 0.03, 0.01-0.11). Patients treated less than what was recommended in St Gallen had cancers in stage 0 (RRR = 21.6, 7.2-64.5), poorly differentiated (RRR = 1.9, 1.2-2.9), HER2 positive (RRR = 3.4, 2.4-4.9) and luminal B-like subtype (RRR = 3.6, 2.6-5.1). Women over 65 years old had a higher probability of being treated less than what was recommended if they had luminal B-like, HER2 or triple negative cancer. Treatment over St Gallen was associated with younger women and less severe cancers, while treatment under St Gallen was associated with older women, more severe cancers and cancers expressing HER2 receptors.es_ES
dc.description.sponsorshipBiological samples were stored at the biobanks supported by Instituto de Salud Carlos III-FEDER: Parc de Salut MAR Biobank (MARBiobanc) (RD09/0076/00036), ‘Biobanco La Fe’ (RD 09 0076/00021) and FISABIO Biobank (RD09 0076/00058), as well as at the Public Health Laboratory of Gipuzkoa, the Basque Biobank, the ICOBIOBANC (sponsored by the Catalan Institute of Oncology), the IUOPA Biobank of the University of Oviedo, and the ISCIII Biobank. SNP genotyping services were provided by the Spanish ‘Centro Nacional de Genotipado’ (CEGEN-ISCIII). We thank all the subjects who participated in the study and all MCC-Spain collaborators. This work was supported by the ‘Acción Transversal del Cancer’, approved by the Spanish Ministry Council on the 11th October 2007, by the Instituto de Salud Carlos III, co-founded by FEDER funds-‘a way to build Europe’ (Grants PI08/1770, PI08/0533, PI08/1359, PI09/00773, PI09/01286, PI09/01903, PI09/02078, PI09/01662, PI11/01403, PI11/01889, PI11/00226, PI11/01810, PI11/02213, PI12/00488, PI12/00265, PI12/01270, PI12/00715, PI12/00150, PI14/01219, PI14/00613, and PI15/00069). Support was also provided by the Fundación Marqués de Valdecilla (Grant API 10/09); the Junta de Castilla y León (Grant LE22A10-2); the Consejería de Salud of the Junta de Andalucía (2009-S0143); the Conselleria de Sanitat of the Generalitat Valenciana (Grant AP 061/10); the Recercaixa (Grant 2010ACUP 00310); the Regional Government of the Basque Country; the Consejería de Sanidad de la Región de Murcia; European Commission grants FOOD-CT-2006-036224-HIWATE; the Spanish Association Against Cancer (AECC) Scientific Foundation; the Catalan Government DURSI (Grant 2014SGR647); the Fundación Caja de Ahorros de Asturias; the University of Oviedo; Societat Catalana de Digestologia; and COST action BM1206 Eucolongene.es_ES
dc.publisherNature Researches_ES
dc.relation.isversionofPublisher's versiones_ES
dc.subjectHealth carees_ES
dc.subjectMedical researches_ES
dc.subjectRisk factorses_ES
dc.titleAdequacy of early-stage breast cancer systemic adjuvant treatment to Saint Gallen-2013 statement: the MCC-Spain study.es_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.contributor.funderInstituto de Salud Carlos IIIes_ES
dc.contributor.funderEuropean Regional Development Fund (ERDF/FEDER)es_ES
dc.contributor.funderFundación Marqués de Valdecillaes_ES
dc.contributor.funderJunta de Castilla y Leónes_ES
dc.contributor.funderGobierno de Andalucíaes_ES
dc.contributor.funderGeneralitat Valencianaes_ES
dc.contributor.funderGobierno Vascoes_ES
dc.contributor.funderGobierno de Murciaes_ES
dc.contributor.funderEuropean Commissiones_ES
dc.contributor.funderAsociación Española Contra el Cánceres_ES
dc.contributor.funderGeneralitat de Catalunyaes_ES
dc.contributor.funderFundación Caja de Ahorros de Asturiases_ES
dc.contributor.funderUniversidad de Oviedoes_ES
dc.contributor.funderSocietat Catalana de Digestologiaes_ES
dc.identifier.journalScientific reportses_ES
dc.repisalud.centroISCIII::Centro Nacional de Epidemologíaes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI08 / 0533es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI09 / 00773es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI09 / 01286es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI09 / 01903es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI09 / 02078es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI09 / 01662es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI11 / 01403es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI11 / 01889es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI11 / 00226es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI11 / 02213es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI12 / 00488es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI12 / 01270es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI12 / 00715es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI12 / 00150es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI14 / 01219es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI14 / 00613es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI15 / 00069es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI08 /1770es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI08 / 1359es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI11 / 01810es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI12 / 00265es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/RD09 0076/00058es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/RD 09 0076/00021es_ES

Files in this item

Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional